💊 Belbuca, Buccal Buprenorphine, and Chronic Pain Separating Fact from Fiction

📰 Medication and Dental Warning

Concerned about dental risks with buprenorphine? Read our full breakdown of FDA warnings, product differences, dental guidance, and current legal context.

Read: Buprenorphine and Dental Damage — What Patients Actually Need to Know →

Purpose. Misinformation can harm patients—like avoiding effective pain treatment due to distorted claims. The goal here is to present verified facts about Belbuca, research evidence, Texas PMP labeling, and key legal developments so patients, advocates, and providers can make informed decisions.

Disclaimer: This page is for educational purposes only and not a substitute for professional medical or legal advice. See full disclaimer.

1. What Is Belbuca?

Pronunciation: Belbuca is pronounced “bell-BOO-kah.”

Belbuca is the brand name of buprenorphine, formulated as a buccal film for moderate to severe chronic pain that requires around-the-clock opioid therapy when other options are inadequate [2], [7], [8].

2. Suboxone vs. Belbuca

Pronunciation: Suboxone is pronounced “suh-BOX-own.”

3. FDA’s 2022 Dental Warning & User Tips

Important context: The FDA warning applies to buprenorphine medications that dissolve in the mouth, including both opioid use disorder products and pain formulations like Belbuca. However, reported dental cases are mainly associated with OUD-based products, particularly Suboxone and similar formulations. Patients should not assume all buprenorphine products carry the same level or type of risk.

On January 12, 2022, the FDA issued a class-wide safety communication warning that all buprenorphine products dissolved in the mouth (including Belbuca) may cause serious dental problems such as cavities, decay, infections, and tooth loss—even in patients without prior dental history [1].

The FDA reported 305 cases of dental problems, 131 of which were serious. Some issues developed within weeks, others after years of use [1].

Key Clarification for Readers

  • Belbuca is the only FDA-approved transmucosal buprenorphine product for chronic pain [7], [8].
  • It is a brand-name buccal film that dissolves inside the cheek [8].
  • All other transmucosal buprenorphine products (Suboxone, Subutex, Zubsolv, Bunavail, Cassipa) are approved for opioid use disorder (OUD), not pain [7].
  • Non-transmucosal products, such as Butrans (patch) and injectable buprenorphine, do not involve the mouth and are not part of the dental risk warning mechanism [1].

When the FDA reported 28 dental cases in patients using buprenorphine for pain, that category is understood to mean Belbuca, since it is the only product that fits [1].

FDA guidance: Let the medicine fully dissolve, rinse with water and swallow, and wait at least 1 hour before brushing teeth to avoid damaging softened enamel [1], [8].

User Tips (opinion only — not FDA guidance)

  • Lightly moisten the inside of the cheek first so the film adheres better.
  • Let it dissolve naturally; don’t rub or move it to speed it up.
  • Rinse with water after it dissolves, swallow, then wait at least 1 hour before brushing.
  • Alternate sides if possible, and tell your dentist where you usually place the film.
  • Keep regular dental visits and let your dentist know you use Belbuca.

Evidence: Peer-reviewed analyses show the strongest dental harm signal with sublingual buprenorphine/naloxone combination products (e.g., Suboxone). Belbuca (a buccal, buprenorphine-only film) carries the FDA’s class warning because it dissolves in the mouth, but there is less published data directly linking Belbuca alone to severe dental injury [4], [1].

Opinion: It is reasonable to suggest that the higher dental risk seen with Suboxone relates not only to buprenorphine itself, but to the combination product and its sublingual formulation, which may expose teeth differently. In our view, this helps explain why Belbuca—while not risk-free—has not triggered the same level of dental litigation as Suboxone.

Opinion: Clinical Insight from My Dentist on Belbuca’s Dental Impact (December 2, 2025)

Opinion / personal experience only — not medical or dental advice.

I just got back from the dentist, and they found a very small early-stage cavity right in the exact area where I normally place my Belbuca film. I asked him directly whether Belbuca could have contributed to it or even caused it.

That’s when he explained it with a really good analogy.

He said medications like Belbuca or Suboxone can play a role, but they are rarely the primary cause by themselves. He compared it to having a pile of wood in your garage. If a little gasoline spills on the wood, nothing will happen unless there’s a spark. But if the wood is already dry and neglected, and then you strike a match, everything catches fire.

In his analogy:

  • The wood = the current condition of your teeth
  • The gasoline = the medication residue
  • The match = poor or inconsistent oral hygiene
  • The fire = the cavity

So yes — the Belbuca may have contributed, especially because it sits on that side of my mouth, but it likely wasn’t the root cause. It can speed things up if your teeth are already vulnerable, but it usually doesn’t “start the fire” alone.

He also said that millions of Americans struggle with dental health in general, and not because they don’t care. The whole system makes it hard:

  • Dental care is extremely expensive.
  • Dental insurance doesn’t cover much.
  • Many people work long hours and skip regular visits.
  • American diets are high in sugar and processed carbs.
  • Hundreds of common medications cause dry mouth (which dramatically increases decay).
  • Chronic pain, illness, and fatigue make routines harder.
  • Many avoid the dentist because of fear or embarrassment.
  • Access to fluoride varies by community.
  • Most adults don’t floss daily.

And honestly — he was right. I haven’t been in for a cleaning in over two years, instead of the recommended every six months. This isn’t just a “me” thing either. It’s well documented that Americans, as a whole, have poor oral hygiene habits and high rates of untreated dental problems.

More recent documented sources:

So while Belbuca can be a contributing factor, it usually isn’t the sole cause. In my case, the cavity is more likely from a combination of the medication sitting in that spot and the fact that I fell behind on regular dental maintenance.

3A. Side Effects

Like most opioid medications, many Belbuca side effects overlap with “class-wide” opioid effects (for example, constipation, nausea, drowsiness, dizziness). Individual response varies by dose, other medications, and health factors. [8], [5], [6]

Common side effects

  • Constipation [8]
  • Nausea and/or vomiting [5]
  • Headache [5]
  • Dizziness or lightheadedness [6]
  • Drowsiness / sleepiness / fatigue [6]
  • Dry mouth (xerostomia) [5], [6]
  • Sweating [5]

Potentially serious side effects (seek medical advice promptly)

  • Slow or shallow breathing (respiratory depression), especially with other sedating substances [8]
  • Severe sleepiness, confusion, or fainting [6]
  • Severe constipation or signs of bowel blockage [8]
  • Allergic reactions (swelling, rash, trouble breathing) [6]

Sources for side effects: Drugs.com (Belbuca side effects) · Cleveland Clinic (buprenorphine buccal film) · FDA Prescribing Information (PDF)

Back to top ↑

4. Harm Reduction & Prevention

  • Let the film dissolve fully, rinse with water, swallow, and wait ≥1 hour before brushing [1].
  • Tell your dentist you use Belbuca; maintain regular check-ups.
  • Manage xerostomia (dry mouth) with hydration, saliva substitutes, or sugar-free gum [5], [6].

5. Labeling Timeline

  • 2015–2021: Belbuca label carried standard opioid warnings (addiction, respiratory depression, misuse).
  • 2022: FDA added a class-wide dental warning to all transmucosal buprenorphine products, including Belbuca [1], [8].

6. Misconceptions vs. Reality

These are some common misconceptions about Belbuca and buprenorphine, and the facts that correct them. Our goal is to provide accurate information so you can make an informed decision. Each patient’s response is unique—genetics, conditions, and other treatments affect how well it works. That’s why we cite references so you can check the sources yourself.

❌ Misconception✅ Reality
“Belbuca is weak.” Belbuca is an opioid analgesic (partial agonist) for moderate to severe pain. VA 2024 highlights safety advantages, not weakness [3], [17].
“Evidence proves it doesn’t work.” Evidence is limited because many studies are small, short-term, or include OUD populations. That reflects a lack of research, not proof of ineffectiveness (studies are often heterogeneous) [3], [11].
“Partial agonist = partial pain relief.” Not true. A partial agonist can still provide robust pain relief within its ceiling [8].
“Buprenorphine is only for addiction.” Incorrect. Belbuca (and Butrans) are FDA-approved for chronic pain; Suboxone is for OUD [7], [8].

7. How Belbuca Compares to Other Pain Medications

Belbuca (buprenorphine) is often misunderstood as “weaker,” but that’s not accurate. Using standard equianalgesic (conversion) references, Belbuca can provide analgesia comparable to commonly prescribed opioids for chronic pain. The key difference is that buprenorphine is a partial agonist with a unique ceiling effect, which changes how increasing the dose translates into additional pain relief.

MedicationRouteApproximate Conversion to Oral MorphineNotes
Morphine Oral 30 mg = 30 mg (baseline) Reference standard
Hydrocodone
(Zohydro, Norco, Hysingla) 		Oral 30 mg ≈ 30 mg oral morphine ~1:1 with morphine (MME)
Oxycodone Oral 20 mg ≈ 30 mg oral morphine ~1.5× stronger than morphine
Hydromorphone (Dilaudid) Oral 7.5 mg ≈ 30 mg oral morphine ~4–7× stronger than morphine
Hydromorphone (Dilaudid) IV 1.5 mg ≈ 10 mg IV morphine ~7× stronger IV
Buprenorphine (Belbuca) Buccal film 0.4 mg ≈ 30 mg oral morphine
0.8 mg ≈ 60 mg oral morphine
1.2 mg ≈ 90 mg oral morphine 		Partial agonist; ceiling effect; very high receptor affinity
Buprenorphine (Butrans) Transdermal patch 20 mcg/hr ≈ 40–60 mg oral morphine/day Long-acting option; ceiling effect applies
Buprenorphine IV/IM 0.3 mg ≈ 10 mg IV morphine Less common for chronic pain in the U.S.

Important: These conversions are approximate; prescribers usually reduce doses when switching to avoid overdose. Unlike oxycodone or hydromorphone, buprenorphine does not keep increasing its effect at higher doses because of its ceiling effect. For many patients, Belbuca provides strong, reliable pain relief with a lower risk of respiratory depression than full agonists.

If there were no ceiling effect: Based on its extremely high μ-opioid receptor affinity, buprenorphine would likely appear “stronger” than oxycodone or even hydromorphone on a milligram-to-milligram basis. In real-world use, the ceiling effect both enhances safety and limits how much additional pain relief is felt at higher doses.

What is MME? Morphine Milligram Equivalents (MME) standardize different opioids to morphine so doses can be compared across medications. For example, 20 mg oxycodone ≈ 30 MME, and 20 mg hydrocodone ≈ 20 MME.[18]

8. What the Evidence Actually Shows

Bottom line: Independent reviews (e.g., VA/DoD 2024) rate the evidence for buprenorphine in chronic pain as low to very low certainty due to small, short-term, or heterogeneous studies. That reflects limitations in the research base—not that the medicine is weak [3].

How VA documents fit together: The VA/DoD 2022 guideline rated buprenorphine’s chronic-pain evidence as low to very low. In 2024, VA Pharmacy Benefits Management published a two-page “Quick Facts” sheet that distills the same conclusion for busy clinicians; it does not replace the 2022 guideline but summarizes it for practice [17], [3].

One clinical trial (Gimbel 2016) showed that buccal buprenorphine provided steady 24-hour relief when dosed every 12 hours, reducing the need for multiple daily doses compared with short-acting opioids. However, this is not conclusive for long-term outcomes without more robust trials [11].

Additional background (not featured as primary evidence): Hale 2017 (48-week open-label extension) and Aiyer 2018 (systematic review) discuss buccal/transdermal buprenorphine but are limited by study design and certainty; they support the VA’s “low certainty” rating but do not establish long-term effectiveness [15], [16].

9. Why You Hear Conflicting Information

Some online sources misquote broad OUD-focused studies and treat them as chronic-pain evidence. That is incorrect. Fear-based messaging spreads faster than careful analysis.

Opinion: A major reason these misconceptions spread is that many people do not take the time to read studies fully or verify whether the research actually applies to chronic pain. In-depth research is time-consuming; shortcuts allow partial quotes and secondhand claims to circulate as “facts.”

If the goal is to help patients and providers, due diligence matters—checking original sources, ensuring they’re relevant (pain vs. OUD), and presenting context. Without this effort, misinformation spreads far faster than corrections.

Why this matters: Patients deserve accurate, relevant facts—not recycled talking points from unrelated studies. That’s why we cite full references so you can read them yourself.

10. Prescription Monitoring & OUD Labeling (Texas Focus)

In Texas, Belbuca prescriptions appear in the Prescription Monitoring Program (PMP) like other opioids. This is for tracking only—it does not diagnose OUD. Being prescribed Belbuca for chronic pain does not label a patient as addicted [9], [10].

Factual caution: While the law is clear, some doctors or pharmacists may misinterpret PMP entries for buprenorphine due to stigma or lack of familiarity. This misuse is not how the system is intended to work.

Important: Texas law (Health & Safety Code § 481.076) defines PMP use as prescription tracking, not diagnosis. Misusing this data to label a patient with OUD is not supported by law. [9]

11. Myths vs. Facts

ClaimFact
“Belbuca labels you with OUD in the Texas PMP.” False. Texas PMP records prescriptions, not diagnoses. Belbuca for pain does not label a patient with OUD [9], [10].
“Belbuca is just as bad for teeth as Suboxone.” All oral-dissolved buprenorphine has some dental risk; the strongest published signal involves sublingual Suboxone. There is currently no Belbuca-specific MDL or consolidated legal action; Suboxone dental litigation is consolidated separately [4], [12].

12. Why Some Articles Are Not Relevant

Two frequently cited sources are not applicable to Belbuca for chronic pain and are included only as background:

  • NCBI/Bookshelf – Opioid Treatments for Chronic Pain — scope and analyses are closely tied to OUD and misuse contexts, not chronic pain management with Belbuca; chronic pain patients were not the focus and were often excluded from key analyses [13].
  • AHRQ Evidence Review — broad opioid review with an emphasis on misuse/OUD risk; it does not provide Belbuca-specific outcomes for chronic pain and is not evidence for or against Belbuca in this population [14].

13. Frequently Asked Questions (FAQ) — Belbuca, Suboxone & Dental Lawsuits

Context: The FDA issued a class-wide dental warning for all transmucosal (mouth-dissolving) buprenorphine products in 2022, but the federal lawsuits focus on Suboxone sublingual film where most harm reports and plaintiffs are concentrated.

Q: Why is there a lawsuit over Suboxone but not Belbuca or Butrans?

A: The litigation targets Suboxone sublingual film because that formulation has the most documented dental harm in practice. According to the FDA, only about 28 dental cases were reported in patients using buprenorphine for pain (understood to be Belbuca), and none for Butrans (patch). By contrast, as of September 2, 2025, 1,882 Suboxone tooth-decay cases were pending in the federal MDL (No. 3092, N.D. Ohio). Because the Court permits batch filings (up to 100 plaintiffs per complaint), the number of individual claimants is likely higher than the raw docket count.[FDA] [MDL] [JPML] [CMO 14]

Q: Didn’t the FDA warn about all buprenorphine products that dissolve in the mouth?

A: Yes. In January 2022, the FDA issued a class-wide safety communication for all transmucosal buprenorphine products. The FDA identified 305 total dental cases (including 131 serious) across the class, with onset ranging from ~2 weeks after starting therapy to years later; only about 28 of those occurred in pain patients (i.e., Belbuca users).[FDA]

Q: So, is the problem buprenorphine itself, or the film?

A: Evidence points to the formulation and route. Suboxone is a sublingual film (under the tongue) that can leave acidic material in prolonged contact with teeth and gums. Belbuca is a buccal film (inside the cheek) with a different exposure pattern, and far fewer cases have been reported. Butrans is a transdermal patch and never contacts the mouth.[FDA]

Q: Could Belbuca still cause dental issues?

A: Yes. Any mouth-dissolving buprenorphine can pose some dental risk, which is why Belbuca also carries the FDA warning. Follow FDA advice: let the film dissolve fully, rinse with water and swallow, and wait ≥1 hour before brushing. Still, out of the 305 cases FDA reviewed, only 28 were in pain patients (Belbuca category).[FDA]

Q: Should patients avoid Belbuca because of this?

A: Not necessarily. Belbuca remains the only FDA-approved transmucosal buprenorphine product for chronic pain, and some patients report excellent relief while others do not. The dental risk is real but comparatively uncommon in pain-patient reports. The right approach is to discuss benefits and risks with your doctor and follow oral-care guidance.[FDA]

14. Conclusion

Belbuca, the brand name of buprenorphine, is a partial agonist. This does not mean it cannot control moderate to severe pain. It means the medicine has a ceiling effect: at lower and mid doses, pain relief increases with dose; at higher doses (≈600–900 mcg), increases extend duration rather than strength [8].

Like all medications, Belbuca is not universally effective. Some patients find significant relief; others do not. Genetics, conditions, and individual factors shape response. That is why treatment must be individualized—not one-size-fits-all.

Too often in Texas (and nationally), blanket policies by government or insurers ignore patient uniqueness. True medical freedom means recognizing individuality and letting doctors and patients decide together, based on evidence and clinical judgment.

P.A.R.T. Texas advocates for compassionate, individualized care and the medical freedom to make treatment decisions without interference.

References

  1. FDA Drug Safety Communication (Jan 12, 2022): FDA – Dental Problems with Buprenorphine Medicines
  2. Belbuca Prescribing Information (includes administration and excipients): Drugs.com – Belbuca Professional Info
  3. VA PBM Academic Detailing – Buprenorphine for Chronic Pain (Quick Facts, Mar 2024): VA PBM Quick Facts
  4. Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease. JAMA. 2022;328(22):2269–2271. Open-access (PMC) | JAMA
  5. Belbuca Side Effects (xerostomia listed among common effects): Drugs.com – Side Effects
  6. Cleveland Clinic – Buprenorphine Buccal Film (patient info): Cleveland Clinic
  7. Official Belbuca manufacturer website: Belbuca.com
  8. Belbuca (buprenorphine buccal film) — Full Prescribing Information, updated Dec 15, 2023 (Supplement S-023). FDA – 2023 Belbuca Label (PDF)
  9. Texas Health & Safety Code § 481.076 — Prescription information program; redisclosure; duties of Texas State Board of Pharmacy. Texas Legislature Online
  10. Texas Prescription Monitoring Program (overview): Texas State Board of Pharmacy – PMP
  11. Gimbel J, et al. (2016). Efficacy and safety of buccal buprenorphine in opioid-experienced patients with moderate-to-severe chronic low back pain: A randomized, double-blind, placebo-controlled trial. Therapeutics and Clinical Risk Management. 12:1275–1285. (Corrected version). PMC (corrected)
  12. U.S. District Court (N.D. Ohio) — MDL 3092: In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation: Official MDL page
  13. NCBI Bookshelf — Opioid Treatments for Chronic Pain (background context): NBK589632
  14. AHRQ Evidence Review (background hub; not Belbuca-specific): effectivehealthcare.ahrq.gov
  15. Hale ME, Urdaneta C, Kirby MT, et al. Long-Term Safety and Efficacy of Buccal Buprenorphine in Patients with Moderate to Severe Chronic Pain. Pain Medicine. 2017;18(7):1222–1231. doi:10.1093/pm/pnw345. PubMed
  16. Aiyer R, Gulati A, Gungor S, Bhatia A. Buprenorphine for Chronic Pain: A Systematic Review. Current Pain and Headache Reports. 2018;22(12):83. doi:10.1007/s11916-018-0730-6. PubMed
  17. VA/DoD Clinical Practice Guideline for the Use of Opioids in the Management of Chronic Pain (Version 4.0, 2022). healthquality.va.gov/guidelines/Pain/cot/
  18. CDC explains MME as a morphine-standardized way to compare opioids and provides examples (e.g., hydrocodone 20 mg = 20 MME; oxycodone 20 mg = 30 MME). See: CDC 2022 Opioid Prescribing Guideline, conversion examples. Additional references discussing morphine as the baseline include: UCSF Pain: Oral Morphine Equivalents and Tan et al., 2022.
  19. U.S. JPML – Pending MDL Statistics Report (Sept 2, 2025): 1,882 actions pending in MDL 3092. JPML PDF
  20. Case Management Order No. 14 (Joinder of Complaints), MDL 3092 — allows up to 100 plaintiffs per complaint. PDF
  • Texas Health & Safety Code § 481.076 — Establishes the Texas PMP as a prescription tracking tool; limits access; does not assign diagnoses [9].
  • FDA Labeling for Belbuca (2019) — Indicates Belbuca for moderate to severe chronic pain requiring around-the-clock opioid therapy; not an OUD medication [8].
  • VA PBM (2024) — Allows buprenorphine for chronic pain when non-opioids are inadequate; notes low/very-low certainty due to limited studies (does not claim proven long-term superiority) [3].
  • Suboxone Dental MDL (context) — Consolidated litigation concerns sublingual buprenorphine/naloxone; there is no Belbuca-specific MDL [12].

Full disclaimer: This site cites laws, regulations, and clinical research for educational purposes. It is not medical advice, legal advice, or a substitute for professional consultation. Patients should speak with licensed providers about treatment decisions. Attorneys should independently research and verify all statutes, rules, and case law before relying on information here.

Back to top ↑